跳至主要内容
临床试验/NCT05852522
NCT05852522招募中不适用

NCT MASTER Plattform Molecularly Aided Stratification for Tumor Eradication Research

German Cancer Research Center1 个研究点 分布在 1 个国家目标入组 10,000 人开始时间: 2018年11月11日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
10,000
试验地点
1
主要终点
overall survival

研究概览

简要总结

NCT/DKFZ/DKTK MASTER is a prospective, continuously recruiting, multicenter observational study for biology-guided stratification of adults with rare cancers, including rare subtypes of common entities, using comprehensive molecular profiling, and clinical decision-making in a multidisciplinary molecular tumor board.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Rare cancer (Incidence <6/100,000 persons/year) or Rare subtype of a more common entity (case-by-case decision; example: pancreatic ductal adenocarcinoma without KRAS mutation)
  • Metastatic and/or locally advanced cancer with no curative therapy option and indication for systemic therapy

排除标准

  • Severe neurological or psychiatric disorder interfering with the ability to give oral and written informed consent

结局指标

主要结局

overall survival

时间窗: 10 years

time period of survival from date of diagnosis

progression free survival

时间窗: 5 years

Time period of progression survival from date of multiomics analysis

次要结局

  • response to antitumor treatment(5 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验